IPO

With profits doubling and a massive cash infusion, Mama's Creations is executing a masterclass in growth. But can its operational engine keep pace?

A top EV battery supplier just went public on the NYSE, but its real target is the AI boom. Can Londian Wason transform into a key player in NVIDIA's world?

Cabbacis is pitching its patented, very-low-nicotine hemp cigarettes to investors, betting its future on a proposed FDA rule to slash nicotine in tobacco.

Inflection Point’s latest SPAC closes a major IPO, but it’s not 2021. This is a story of seasoned players, mixed track records, and a hunt for real disruption.

Samsung Biologics is raising KRW 3 trillion to buy a peptide specialist and build a mega-campus. It's a bold play that trades short-term dilution for long-term dominance.

Fintech giant GCash is turning millions of everyday Filipinos into stock market investors, democratizing wealth and reshaping the nation's economic landscape.

JATT III Acquisition Corp's $60M IPO isn't just another SPAC. It’s a calculated bet by a proven team on the future of AI in drug discovery. But does it signal a new era for biotech M&A?

Estonian developer Hepsor AS is offering a 9.50% unsecured bond. We analyze if this high-yield opportunity is a strategic masterstroke or a risky wager.

Andersen Group insiders cashed out $216.8M in a secondary offering. The company saw no cash, but the move signals market confidence and reshapes its future.

A Boston biotech with Korean roots just went public in Seoul. Its goal: to repair the body's smallest blood vessels, a market Merck has already bet billions on.

A new space-focused SPAC has launched, but will it reach orbit in a market demanding experienced pilots and proven flight plans over speculative fuel?

A New Zealand tech firm’s public debut isn't just about mowers. It’s a strategic play for a future where robotics and solar power untether us from the grid.

MDB Capital celebrates a string of successful IPOs but reports a staggering $16.1M loss, putting its unique 'public venture' model under intense scrutiny.

A San Diego biotech is advancing a device to clean the blood of disease-fueling particles. With early promise in cancer and a new path in Long COVID, can it navigate the financial realities of innovation?

Curis secures a crucial, albeit small, $5.6M funding lifeline. Will it be enough to push its promising cancer drug through trials before the clock runs out?

With a blockbuster IPO and dazzling growth, Bending Spoons looks unstoppable. But a closer look reveals a high-stakes strategy built on massive debt.

As Standard Nuclear preps its first earnings call post-IPO, the real story is its pivotal role in a new industrial revolution powered by advanced nuclear fuel.

Liftoff Mobile reported a net loss, but a look past the IPO-related accounting reveals a company firing on all cylinders, with its AI platform driving record revenue.

Beyond a 23% profit surge, ILCO's latest results reveal a blueprint for resilience through strategic IPOs, dividends, and a diversified portfolio.

With a cash runway into 2029, Avalyn Pharma is advancing a novel inhaled drug platform, hitting key clinical milestones to challenge an oral-dominated market.